W. Amick
Director/Board Member at BioRexis Pharmaceutical Corp.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Frederick W. Kyle | M | - |
BioRexis Pharmaceutical Corp.
 BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | - |
| Karen Ho Hong | M | 52 |
BioRexis Pharmaceutical Corp.
BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | - |
| Matt Rieke | M | - |
BioRexis Pharmaceutical Corp.
BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gregory R. Cox | M | 58 | 10 years | |
| John Johnson | M | 66 | 3 years | |
| Martin Murphy | M | 81 |
Aldagen, Inc.
 Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | - |
| Roy N. Davis | M | 77 |
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | 28 years |
| John Tattory | M | 58 | 12 years | |
| John Leone | M | 77 | 9 years | |
| Herbert H. McDade | M | 97 | 15 years | |
| Mary Templeton | F | 78 | - | |
| Brad H. Vale | M | 72 |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | 23 years |
| David P. Holveck | M | 79 |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | 9 years |
| David Lopez | M | 65 | 11 years | |
| Max E. Link | M | 84 | 17 years | |
| Bruce Peacock | M | 72 | 11 years | |
| Dennis Fenton | M | 72 | 4 years | |
| Lyle A. Hohnke | M | 80 |
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | 4 years |
| David L. Urdal | M | 74 | 20 years | |
| James M. Hinson | M | 73 |
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | - |
| Russell Clayton | M | 63 | - | |
| Joseph M. Mahady | M | 71 | 8 years | |
| Kathleen A. McGowan | F | 63 | 4 years | |
| Thomas Miller | M | 52 | 11 years | |
| Bogdan Dziurzynski | M | 75 | 14 years | |
| Staf van Reet | M | - |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | 4 years |
| Shing-Yin Tsui | F | 53 | 16 years | |
| Parvinder S. Hyare | M | - |
Ortho Biotech Products LP
 Ortho Biotech Products LP Pharmaceuticals: MajorHealth Technology Ortho Biotech Products LP provides innovative products and services which are designed to enhance the lives of individuals with serious chronic illnesses. The company's products include PROCRIT, DOXIL and LEUSTATIN. Ortho Biotech Products was founded in 1990 and is headquartered in Bridgewater, NJ | 8 years |
| Lisa M. Caperelli | F | - | 8 years | |
| Bill Jenkinson | M | - | 1 years | |
| David P. Carberry | M | 71 |
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | 3 years |
| Lindsay Rocco | F | - | 2 years | |
| Thomas Hoy | M | 62 | 5 years | |
| Laurence Keller | M | - |
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | 2 years |
| Gerald J. Orehostky | M | 57 | 2 years | |
| Ralph Christopher Cavalli | M | 65 | 7 years | |
| Jing Wang | M | - |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | - |
| Raymond Bower | M | - |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | 2 years |
| Anne C. Maffei | F | - |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | 2 years |
| Blair Flicker | M | - |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | - |
| John L. Cassis | M | 75 |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | 3 years |
| Christopher Schaber | M | 57 | 8 years | |
| Loretta Itri | M | 74 |
Ortho Biotech Products LP
Ortho Biotech Products LP Pharmaceuticals: MajorHealth Technology Ortho Biotech Products LP provides innovative products and services which are designed to enhance the lives of individuals with serious chronic illnesses. The company's products include PROCRIT, DOXIL and LEUSTATIN. Ortho Biotech Products was founded in 1990 and is headquartered in Bridgewater, NJ | 6 years |
| Deni M. Zodda | M | 70 | 6 years | |
| Ralph Niven | M | 64 | 4 years | |
| Antonio Esteve Cruella | M | 66 | 11 years | |
| Hal R. Werner | M | 75 |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | - |
| Mark G. Osterman | M | - | 2 years | |
| Charles F. Katzer | M | 74 | 4 years | |
| Joel R. Kimbrough | M | 66 |
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | - |
| Steven J. Gavel | M | - | - | |
| Kathryn Cole | F | 59 | 15 years | |
| Rick S. Kent | M | 74 |
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | 2 years |
| William Edward Evans | M | 74 |
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | - |
| Robert Capetola | M | 73 | 13 years | |
| Dana Gelbaum | F | - |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | 4 years |
| Roger J. Guidi | M | - |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | 11 years |
| Zeev Zehavi | M | - |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | 23 years |
| Ting Oei | M | - |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | 11 years |
| Adam T. Rumage | M | - | 9 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 60 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- W. Amick
- Personal Network
